EU CHMP Recommends Marketing Authorisation for Rasonque
The EMA’s Committee for Medicinal Products for Human Use recommended granting marketing authorisation for Rasonque for metastatic pancreatic cancer in the EU.
The EMA’s Committee for Medicinal Products for Human Use recommended granting marketing authorisation for Rasonque for metastatic pancreatic cancer in the EU.